Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3

Muhammad Sabbah; Karsten Veien; Matti Niemela; Phillip Freeman; Rickard Linder; Dan Ioanes; Christian Juhl Terkelsen; Olli A Kajander; Sasha Koul; Mikko Savontaus; Pasi Karjalainen; Andrejs Erglis; Mikko Minkkinen; Troels Jørgensen; Lars Sondergaard; Ole De Backer; Thomas Engstrøm; Jacob Lønborg

doi:10.1016/j.ahj.2022.10.009

Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3

Muhammad Sabbah, Karsten Veien, Matti Niemela, Phillip Freeman, Rickard Linder, Dan Ioanes, Christian Juhl Terkelsen, Olli A Kajander, Sasha Koul, Mikko Savontaus, Pasi Karjalainen, Andrejs Erglis, Mikko Minkkinen, Troels Jørgensen, Lars Sondergaard, Ole De Backer, Thomas Engstrøm, Jacob Lønborg

Institut for Klinisk Medicin - Hjertesygdomme

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

16 Downloads (Pure)

Abstract

BACKGROUND: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes.

STUDY DESIGN: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI.

SUMMARY: NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.

Originalsprog	Engelsk
Tidsskrift	American Heart Journal
Vol/bind	255
Sider (fra-til)	39-51
Antal sider	13
ISSN	0002-8703
DOI	https://doi.org/10.1016/j.ahj.2022.10.009
Status	Udgivet - jan. 2023

Adgang til dokumentet

10.1016/j.ahj.2022.10.009Licens: CC BY

1-s2.0-S0002870322002046-mainForlagets udgivne version, 596 KBLicens: CC BY

Fingeraftryk

Dyk ned i forskningsemnerne om 'Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Sabbah, M., Veien, K., Niemela, M., Freeman, P., Linder, R., Ioanes, D., Terkelsen, C. J., Kajander, O. A., Koul, S., Savontaus, M., Karjalainen, P., Erglis, A., Minkkinen, M., Jørgensen, T., Sondergaard, L., De Backer, O., Engstrøm, T., & Lønborg, J. (2023). Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3. American Heart Journal, 255, 39-51. https://doi.org/10.1016/j.ahj.2022.10.009

@article{8a33004842b84c33a3b8a20384f011bd,

title = "Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3",

abstract = "BACKGROUND: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes.STUDY DESIGN: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI.SUMMARY: NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.",

keywords = "Aortic Valve Stenosis/complications, Aortic Valve/surgery, Constriction, Pathologic, Coronary Angiography, Coronary Artery Disease/complications, Fractional Flow Reserve, Myocardial, Humans, Percutaneous Coronary Intervention/adverse effects, Transcatheter Aortic Valve Replacement/adverse effects, Treatment Outcome",

author = "Muhammad Sabbah and Karsten Veien and Matti Niemela and Phillip Freeman and Rickard Linder and Dan Ioanes and Terkelsen, {Christian Juhl} and Kajander, {Olli A} and Sasha Koul and Mikko Savontaus and Pasi Karjalainen and Andrejs Erglis and Mikko Minkkinen and Troels J{\o}rgensen and Lars Sondergaard and {De Backer}, Ole and Thomas Engstr{\o}m and Jacob L{\o}nborg",

year = "2023",

month = jan,

doi = "10.1016/j.ahj.2022.10.009",

language = "English",

volume = "255",

pages = "39--51",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby, Inc",

}

Sabbah, M, Veien, K, Niemela, M, Freeman, P, Linder, R, Ioanes, D, Terkelsen, CJ, Kajander, OA, Koul, S, Savontaus, M, Karjalainen, P, Erglis, A, Minkkinen, M, Jørgensen, T, Sondergaard, L, De Backer, O, Engstrøm, T & Lønborg, J 2023, 'Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3', American Heart Journal, bind 255, s. 39-51. https://doi.org/10.1016/j.ahj.2022.10.009

Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3. / Sabbah, Muhammad; Veien, Karsten; Niemela, Matti et al.
I: American Heart Journal, Bind 255, 01.2023, s. 39-51.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation - the third nordic aortic valve intervention trial - NOTION-3

AU - Sabbah, Muhammad

AU - Veien, Karsten

AU - Niemela, Matti

AU - Freeman, Phillip

AU - Linder, Rickard

AU - Ioanes, Dan

AU - Terkelsen, Christian Juhl

AU - Kajander, Olli A

AU - Koul, Sasha

AU - Savontaus, Mikko

AU - Karjalainen, Pasi

AU - Erglis, Andrejs

AU - Minkkinen, Mikko

AU - Jørgensen, Troels

AU - Sondergaard, Lars

AU - De Backer, Ole

AU - Engstrøm, Thomas

AU - Lønborg, Jacob

PY - 2023/1

Y1 - 2023/1

N2 - BACKGROUND: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes.STUDY DESIGN: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI.SUMMARY: NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.

AB - BACKGROUND: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes.STUDY DESIGN: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI.SUMMARY: NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.

KW - Aortic Valve Stenosis/complications

KW - Aortic Valve/surgery

KW - Constriction, Pathologic

KW - Coronary Angiography

KW - Coronary Artery Disease/complications

KW - Fractional Flow Reserve, Myocardial

KW - Humans

KW - Percutaneous Coronary Intervention/adverse effects

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Treatment Outcome

U2 - 10.1016/j.ahj.2022.10.009

DO - 10.1016/j.ahj.2022.10.009

M3 - Journal article

C2 - 36220354

SN - 0002-8703

VL - 255

SP - 39

EP - 51

JO - American Heart Journal

JF - American Heart Journal

ER -